Test Home2021-06-07T10:17:32+02:00

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

The Psyence™ Group sets the global standard for natural psychedelics.

Informed by nature and guided by science, Psyence is a life science biotechnology company pioneering the use of natural psilocybin to heal psychological trauma and the diagnosable disorders that can result: anxiety, depression, PTSD, stress, grief and bereavement. We have a focus on these conditions in the context of palliative care.

We are focused on the development of psilocybin medical products for research institutions and clinics and will also manufacture regulatory-compliant over the counter psilocybin containing products. We are also developing nutraceutical products for depression, acute anxiety and sleep disorders.

Psyence is listed on the Canadian Stock Exchange (CSE: PSYG) and our diversified business has a global footprint with operations in multiple legal jurisdictions. We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world in Southern Africa.

Psyence is pioneering the use of natural psilocybin for the long-term treatment of trauma and its mental health consequences.

[layerslider id=”2″ /]

Bringing together leaders in the business of medicine and science

Our scientific and medical team, which includes experts in neurology, neuroscience, oncology and drug development, have international expertise in palliative medicine and science. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.

THerapuetics_Logo 400pxwide

We develop natural psilocybin products, medicinal formulations and treatment protocols to treat mental health disorders in a clinical environment.

production_Logo 400pxwide

We operate one of the first federally licensed commercial psilocybin cultivation and production facilities in the world.

Psyece Funcitonblue 400px

With experience in building disruptive brands and creating routes to market, we are focused on the development of over-the-counter proprietary nutraceutical products.

Psyence_Logo 400pxwide

We will partner with experienced providers of retreats and clinics in legal jurisdictions to inform our medical and product development strategy.

Our News

  • Corporate Updates - Psyence

Psyence Group Corporate Update

July 12, 2023|

Since Psyence’s corporate update issued in June 2022, the Company has made significant progress in its clinical trial programs and in upgrading its production facility and extraction capabilities. Psyence is executing on its strategy and is pleased to provide an update across the pillars of the business.

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Our News

  • Psyence Production Expands Capability

Psyence Production Expands Capability

October 30, 2023|

Psyence recently designed a new laboratory at the facility in order to expand its extraction capabilities. The building of the laboratory has since commenced and is expected to be completed in Q4 2023. The expansion fits under the existing building footprint, and once completed, new state-of-the-art extraction equipment will be installed to enhance its current extraction capabilities. There are multiple potential benefits to on-site extraction including increased product shelf life, a more stabilized format for export, and reduced transport costs.

Our Global Footprint

Our team and operations are located across Toronto, Canada; Washington DC, United States of America; Cape Town, South Africa; Kolojane, Kingdom of Lesotho; Kingston, Jamaica; London United Kingdom; Sydney, Australia and Sao Paulo, Brazil.

Go to Top